By: Digital CFO Asia Newsroom | 21 Jan 2021
Novotech Health Holdings, the largest biotech specialist contract research organization (CRO) in Asia, appoints Zidong Zhang as their new CFO with effect from 4 January 2021. Zidong Zhang will be responsible for all aspects of financial management and work closely with Novotech Holdings’ executive team to support the growth of the business across Asia.
Zhang has held numerous finance & digital transformation roles. Most recently, Zhang was the CFO at Henlius Biotech, a Hong Kong-listed global biopharmaceutical company based in Shanghai, where he built and managed the finance team and played an integral role in the company’s initial public offering in 2019. Prior to that, Zhang was an equity research analyst at UBS in New York. He also previously served as Senior Consultant for Bayer A.G in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.
Dr. Zhang holds a PhD in Biochemistry from Boston University, an MBA from Duke University, and a BS in Chemistry from Fudan University. Connect with Dr Zhang on Linkedin.